Search

Abstract Background The coronavirus disease (COVID)-19 pandemic has affected many aspects of life, including pregnancy, childbirth, and safe motherhood so that pregnancy and childbirth take place in completely novel and unusual conditions for people. Therefore, we aimed to determine the opportunities, threats, and needs of pregnant women during a crisis. Methods The present qualitative study was conducted among women who had a history of pregnancy and childbirth during the COVID-19 pandemic period in 2022. The data were collected by conducting face-to-face, semi-structured and in-depth interviews with 20 purposefully selected participants. Interviews continued until data saturation was attained. Data were analyzed through conventional qualitative content analysis based on the Graneheim and Lundman approach. Results The data were categorized under three main themes: 1(“Opportunities for safe motherhood in crisis“(2 Sub‑themes), 2) “Threats to safe motherhood in crisis“(2 Sub‑themes), and 3) “Needs for safe motherhood in crisis” (3 Sub‑themes). Conclusions Crisis is not always a threat. By developing an awareness of the opportunities, threats, and needs that safe motherhood faced during the COVID-19 crisis, policy makers can identify the existing gaps affecting the health of mothers and take the necessary measures to improve their conditions, experiences, and health in further crises.

Background and Objective: Sexual function is an important aspect of quality of life, and reflects on the physical, psychological and mental well being of the individual. The aim of this study was to compare the effects of Tibolone on sexual function, in healthy postmenopausal women. Materials and Methods: This randomized clinical trial study was done on 96 postmenopausal women with no absolute contraindication for hormone replacement therapy. Women were divided into two groups: 52 women in Tibolone group received Tibolone 2.5mg/day + Ca-D (500 mg +200 IU) and 44 women in placebo group received only Ca-D (500 mg +200 IU) for six months. Blood samples were collected at baseline and after 6 months of treatment for hormone determinations. Sexual function was assessed by female sexual function index (FSFI) in six domains. Side effect and satisfaction was assessed. Data was analyzed by Paired and independent t-test, Chi Square and Mann-Whitney tests. Results: 41 women in Tibolone group and 40 women in placebo completed the study. Compare to baseline values and placebo, the Tibolone group significantly improved on all of six FSFI domains (P